External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival
Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. The standard first-line therapy for DLBCL consists of rituximab cyclophosphamide doxorubicin vincristine and prednisone (R-CHOP). About 50–70% of patients may be cured by R-CHOP. There was no data on external va...
Main Authors: | Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2147916 |
Similar Items
-
PB2103: CAN WE ACCURATELY PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA IN THE RITUXIMAB ERA? RETROSPECTIVE COMPARISON OF IPI, AAIPI, R-IPI AND NCCN-IPI
by: P. Chorão, et al.
Published: (2022-06-01) -
IPI: uma abordagem constitucional
by: Guilherme Luis Muramatsu Pereira, et al.
Published: (2009-07-01) -
The history of the International Polar Years (IPYs) /
by: Barr, Susan
Published: (c201) -
PRINTsIPY DIAGNOSTIKI RANNEGO REVMATOIDNOGO ARTRITA
by: I B Belyaeva, et al.
Published: (2005-06-01) -
Record linkage improves assessment of interpregnancy interval (IPI)
by: Christine Roberts, et al.
Published: (2017-04-01)